SCHEMBL1368566

SCHEMBL1368566

NC(=O)CCSc1cccc(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.49
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
PARP1 P09874 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 2/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP2C9 P11712 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 2/20 0.40
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447638 0.85 ALDH1A1 (0.51) MAOACA1CA2CA4CA7
SCHEMBL671196 0.83 MAOA (0.49) MAOACA1CA2CA4CA7
SCHEMBL11217165 0.83 SMN1; SMN2 (0.62) MAOACA1CA2CA4CA7
SCHEMBL30753727 0.80 MAOA (0.58) MAOACA1CA2CA4CA7
SCHEMBL23704885 0.80 KMT2A (0.47) MAOACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL6191672 0.79 ALDH1A1 (0.67) MAOACA1CA2CA4CA7
SCHEMBL953807 0.78 CYP1A2 (0.65) CYP1A2CYP3A4CYP2D6CYP2C19MEN1
SCHEMBL235913 0.78 MAOA (0.58) MAOACA1CA2CA4CA7
SCHEMBL5450459 0.77 MAPT (0.47) MAOACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL238114 0.77 MAOA (0.51) MAOACA1CA2CA4CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067599-B2 Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors HOFFMAN-LA ROCHE INC. (US) 2011-11-29 US disclosed
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP3K5, MAP3K1, PRKACA MAOA 1754/4885CA1 4795/4885CA2 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.